Market closed
10x Genomics/$TXG
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About 10x Genomics
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
Ticker
$TXG
Sector
Trading on
Industry
Life Sciences Tools & Services
Headquarters
Employees
1,306
Website
10x Genomics Metrics
BasicAdvanced
$1.3B
-
-$1.52
1.85
-
Price and volume
Market cap
$1.3B
Beta
1.85
52-week high
$40.30
52-week low
$9.27
Average daily volume
3.3M
Financial strength
Current ratio
4.968
Quick ratio
4.091
Long term debt to equity
10.326
Total debt to equity
11.633
Interest coverage (TTM)
-48,639.75%
Management effectiveness
Return on assets (TTM)
-12.77%
Return on equity (TTM)
-25.17%
Valuation
Price to revenue (TTM)
2.132
Price to book
1.86
Price to tangible book (TTM)
1.92
Price to free cash flow (TTM)
-193.506
Growth
Revenue change (TTM)
-1.28%
Earnings per share change (TTM)
-30.36%
3-year revenue growth (CAGR)
7.59%
3-year earnings per share growth (CAGR)
42.17%
What the Analysts think about 10x Genomics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for 10x Genomics stock.
10x Genomics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
10x Genomics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
10x Genomics News
AllArticlesVideos
Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties
Benzinga·4 weeks ago
10x Genomics, Inc. (TXG) Q4 2024 Earnings Call Transcript
Seeking Alpha·4 weeks ago
Cathie Wood dumped Palantir to buy these biotech stocks
Finbold·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for 10x Genomics stock?
10x Genomics (TXG) has a market cap of $1.3B as of March 13, 2025.
What is the P/E ratio for 10x Genomics stock?
The price to earnings (P/E) ratio for 10x Genomics (TXG) stock is 0 as of March 13, 2025.
Does 10x Genomics stock pay dividends?
No, 10x Genomics (TXG) stock does not pay dividends to its shareholders as of March 13, 2025.
When is the next 10x Genomics dividend payment date?
10x Genomics (TXG) stock does not pay dividends to its shareholders.
What is the beta indicator for 10x Genomics?
10x Genomics (TXG) has a beta rating of 1.85. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.